ProKidney Corp. (PROK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProKidney Corp. (PROK) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.60 Million) by net assets ($318.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ProKidney Corp. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ProKidney Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of ProKidney Corp. for a breakdown of total debt and financial obligations.
ProKidney Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProKidney Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anavex Life Sciences Corp
NASDAQ:AVXL
|
-0.056x |
|
China Metal Products Co Ltd
TW:1532
|
0.089x |
|
Boryszew SA
WAR:BRS
|
-0.014x |
|
Yem Chio Co Ltd
TW:4306
|
0.027x |
|
SPC Samlip Co Ltd
KO:005610
|
0.073x |
|
Shenzhen Magic Design & Decoration Engineering Co Ltd
SHE:002856
|
-0.234x |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
-0.431x |
|
NeXGold Mining Corp
V:NEXG
|
-0.046x |
Annual Cash Flow Conversion Efficiency for ProKidney Corp. (2019–2024)
The table below shows the annual cash flow conversion efficiency of ProKidney Corp. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see PROK company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $401.64 Million | $-126.35 Million | -0.315x | -36.68% |
| 2023-12-31 | $391.34 Million | $-90.07 Million | -0.230x | -50.76% |
| 2022-12-31 | $504.94 Million | $-77.09 Million | -0.153x | +91.83% |
| 2021-12-31 | $26.92 Million | $-50.30 Million | -1.869x | +26.80% |
| 2020-12-31 | $9.86 Million | $-25.18 Million | -2.553x | -52690.69% |
| 2019-12-31 | $15.88 Million | $-76.81K | -0.005x | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more